HEXO Corp is proud to announce that it has launched medical cannabis products in Israel through a 24-month agreement with leading Israeli medical cannabis company, Breath of Life International Ltd. (“BOL”).
HEXO Corp. today announced the final closing of its previously announced early conversion option (the “Early Conversion Option”) in respect of $29.86 million aggregate principal amount of its outstanding $70 million aggregate principal amount of 8% unsecured convertible debentures maturing December 5, 2022 (the “Debentures”).
HEXO Corp. today announced that it completed the previously disclosed sale of its Niagara, Ontario facility for proceeds of approximately $10.25 million on June 15, 2020.
ANNUAL PRODUCTION CAPACITY
POINTS OF QUALITY CONTROL
Want to keep in touch? We’ll send you our latest updates. You can unsubscribe at any time.